| Project/Area Number |
26461104
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
HIRONO Satoru 新潟大学, 医歯学総合病院, 特任教授 (40401765)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小澤 拓也 新潟大学, 医歯学系, 講師 (70467075)
須田 将吉 新潟大学, 医歯学総合病院, 医員 (70714509)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | 冠動脈石灰化 / RANKL / 骨粗鬆症 / デノスマブ |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to investigate the effect of denosumab, a receptor activator for NF-κB ligand (RANKL), on vascular calcifications in patients with ischemic heart disease and osteoporosis.Female patients with both ischemic heart disease and osteoporosis were included in the study. We performed cardiac computed tomography to evaluate coronary artery calcification using the Agatston score. Then, one year after administration of denosumab, we measured their coronary calcium score as the primary outcome and compared their scores with those of a control group of female patients.
The study included 10 patients receiving denosumab treatment. Mean age was 75.7±6.3 years. The average bone density improved from 0.662±0.11 g/cm2 to 0.679±0.12 g/cm2. Calcium score improved from 366.5±438.0 to 362.9±435.1. Results show that osteoporosis therapy with a RANKL inhibitor effectively inhibits the progression of coronary calcifications.
|
